Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?CASCONE, Tina; HEYMACH, John V.Journal of clinical oncology. 2012, Vol 30, Num 4, pp 441-444, issn 0732-183X, 4 p.Article

The convergent development of molecular-targeted drugs for cancer treatment and preventionLIPPMAN, Scott M; HEYMACH, John V.Clinical cancer research. 2007, Vol 13, Num 14, pp 4035-4041, issn 1078-0432, 7 p.Article

Lung CancerHERBST, Roy S; HEYMACH, John V; LIPPMAN, Scott M et al.The New England journal of medicine. 2008, Vol 359, Num 13, pp 1367-1380, issn 0028-4793, 14 p.Article

International conference: Early Stage Lung Cancer: New Approaches to Evaluation and Treatment, Cambridge, MA, USA, October 1-2, 2004LYNCH, Thomas J; GURUBHAGAVATULA, Sarada; HEYMACH, John V et al.Clinical cancer research. 2005, Vol 11, Num 13, issn 1078-0432, 90 p., 2Conference Proceedings

Farnesyl transferase inhibitors for patients with lung cancerJOHNSON, Bruce E; HEYMACH, John V.Clinical cancer research. 2004, Vol 10, Num 12, pp 4254s-4257s, issn 1078-0432, 2Conference Paper

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non―Small-Cell Lung CancerWELSH, James W; KOMAKI, Ritsuko; CHEN, Su S et al.Journal of clinical oncology. 2013, Vol 31, Num 7, pp 895-902, issn 0732-183X, 8 p.Article

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE TrialBLUMENSCHEIN, George R; SAINTIGNY, Pierre; KIES, Merrill S et al.Clinical cancer research (Print). 2013, Vol 19, Num 24, pp 6967-6975, issn 1078-0432, 9 p.Article

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeIHLE, Nathan T; BYERS, Lauren A; LIXIA DIAO et al.Journal of the National Cancer Institute. 2012, Vol 104, Num 3, pp 228-239, issn 0027-8874, 12 p.Article

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article

Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor EfficacyMEHRAN, Reza; NILSSON, Monique; RIEDEL, Bernhard et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 10, pp 2731-2741, issn 0008-5472, 11 p.Article

The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARARABELLINO, Andrea; CARTER, Brandon; PAOLO SCAGLIONI, Pier et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 9, pp 2275-2284, issn 0008-5472, 10 p.Article

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung CancerHEYMACH, John V; PAZ-ARES, Luis; BONOMI, Philip D et al.Journal of clinical oncology. 2008, Vol 26, Num 33, pp 5407-5415, issn 0732-183X, 9 p.Article

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancerKAMAT, Aparna A; TAE JIN KIM; HEYMACH, John V et al.Cancer research (Baltimore). 2007, Vol 67, Num 1, pp 281-288, issn 0008-5472, 8 p.Article

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerHEYMACH, John V; NILSSON, Monique; BLUMENSCHEIN, George et al.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4441s-4445s, 2Conference Paper

CXCR2 Expression in Tumor Cells is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung AdenocarcinomaSAINTIGNY, Pierre; MASSARELLI, Erminia; LIZHANG et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 2, pp 571-582, issn 0008-5472, 12 p.Article

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung CancerCARDNELL, Robert J; YING FENG; BYERS, Lauren A et al.Clinical cancer research (Print). 2013, Vol 19, Num 22, pp 6322-6328, issn 1078-0432, 7 p.Article

Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with PazopanibNIKOLINAKOS, Petros G; ALTORKI, Nasser; YANKELEVITZ, David et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 6, pp 2171-2179, issn 0008-5472, 9 p.Article

Inhibition of Intra-Abdominal Adhesion Formation With the Angiogenesis Inhibitor SunitinibKIM, Sendia; LEE, Sang; GREENE, Arin K et al.The Journal of surgical research. 2008, Vol 149, Num 1, pp 115-119, issn 0022-4804, 5 p.Article

Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomySAKURAI, Maromi K; LEE, Sang; ARSENAULT, Danielle A et al.American journal of physiology. Lung cellular and molecular physiology. 2007, Vol 36, Num 3, issn 1040-0605, L742-L747Article

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceAVERETT BYERS, Lauren; LIXIA DIAO; NILSSON, Monique B et al.Clinical cancer research (Print). 2013, Vol 19, Num 1, pp 279-290, issn 1078-0432, 12 p.Article

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic ResistanceKOPETZ, Scott; HOFF, Paulo M; LIEU, Christopher et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 453-459, issn 0732-183X, 7 p.Article

Novel agents in the treatment of lung cancer : Fourth cambridge conferenceLYNCH, Thomas J; BONOMI, Philip D; PEREZ-SOLER, Roman et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4583s-4586s, 2Conference Paper

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsKULKE, Matthew H; BERGSLAND, Emily K; MICHELINI, Ann et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3555-3561, issn 0732-183X, 7 p.Article

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature Circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activityBEAUDRY, Paul; FORCE, Jeremy; NAUMOV, George N et al.Clinical cancer research. 2005, Vol 11, Num 9, pp 3514-3522, issn 1078-0432, 9 p.Article

Therapeutic efficacy of endostatin exhibits a biphasic dose-response curveCELIK, Ilhan; SÜRÜCÜ, Oguzkan; DIETZ, Carsten et al.Cancer research (Baltimore). 2005, Vol 65, Num 23, pp 11044-11050, issn 0008-5472, 7 p.Article